Print Page | Close Window

Press Releases

Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
06/12/19Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or MelanomaPrinter Friendly Version
05/22/19Alkermes to Present New Data From Mental Health Portfolio at the American Society of Clinical Psychopharmacology 2019 Annual MeetingPrinter Friendly Version
05/14/19Alkermes to Present at the UBS Global Healthcare ConferencePrinter Friendly Version
05/13/19Alkermes to Showcase Leadership in Schizophrenia With New Data Presentations at Upcoming Scientific ConferencesPrinter Friendly Version
04/25/19Alkermes Plc Reports First Quarter 2019 Financial ResultsPrinter Friendly Version
04/24/19Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and MarketingPrinter Friendly Version
04/18/19Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial ResultsPrinter Friendly Version
04/09/19Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of SchizophreniaPrinter Friendly Version
04/08/19Alkermes Announces Departure of Jim RobinsonPrinter Friendly Version
04/03/19Alkermes Expands Awards Program With Focus on Advancing Research in SchizophreniaPrinter Friendly Version
04/01/19Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research SocietyPrinter Friendly Version
03/21/19Alkermes Statement on National Academies of Sciences, Engineering, and Medicine Report on Medications for Opioid Use DisorderPrinter Friendly Version
03/05/19Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care ConferencePrinter Friendly Version
02/26/19Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid TumorsPrinter Friendly Version
02/25/19Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple SclerosisPrinter Friendly Version
02/20/19Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare ConferencePrinter Friendly Version
02/19/19Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer TherapiesPrinter Friendly Version
02/14/19Alkermes Plc Reports Financial Results for the Year Ended Dec. 31, 2018 and Provides Financial Expectations for 2019Printer Friendly Version
02/07/19Alkermes to Host Conference Call to Discuss Fourth Quarter and Year-End 2018 Financial ResultsPrinter Friendly Version
02/01/19Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug ApplicationPrinter Friendly Version
01/16/19Alkermes Announces Recipients of 1st Annual ALKERMES PATHWAYS RESEARCH AWARDS (SM) ProgramPrinter Friendly Version
01/02/19Alkermes' Corporate Presentation to be Webcast at the 37th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version